Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

664.25 -16.36 (-2.40%)
Streaming Delayed Price Updated: 2:58 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
The company is also facing off with biosimilars for standard Eylea and competition with Roche. 
Via Investor's Business Daily
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Via Benzinga
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
From Faruqi & Faruqi, LLP
Via Business Wire
Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
REGN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit On Behalf Of Regeneron Pharmaceuticals, Inc. Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
Exposures Product Safety
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
Via The Motley Fool
Healthcare And Biotech Stocks Continue Their Slide
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025. 
Via Benzinga
Exposures Product Safety
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back... 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.